These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17418607)

  • 1. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
    Lafontan M; Piazza PV; Girard J
    Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
    Scheen AJ; Paquot N; Van Gaal LF
    Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
    Dibble CT; Gelfand EV; Cannon CP
    Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoid system and cardiometabolic risk.
    Saavedra LE
    Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
    Scheen AJ; Paquot N
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
    Després JP; Lemieux I; Alméras N
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.